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The Kidney Stone Center of the Pacific (KSCoP) currently 
provides statewide services for kidney lithotripsy. The non-invasive 
technique uses shock waves to disintegrate kidney stones. Extra-
corporeal shockwave lithotripsy ( ESWL) can be used successfully 
in 85% to 90% of kidney stone patients when surgery is indicated1• 
The success of lithotripsy for the treatment of kidney stones 
aroused the interest of physicians treating biliary (gallbladder) 
disease as well as the vendors oflithotripsy devices; kidney stones 
affect only one-tenth as many people as do gallstones. Because of 
the anatomical problems in treating gallstones, design modifica-
tions had to be made to the first kidney lithotripters in order to adapt 
to the imaging, patient positioning, and specifically for therapy 
focusing required for treatment of gallstones. The Food and Drug 
Administration (FDA) approved clinical trials for biliary lithotripsy 
in the United States in 1988. Ithasbeenestimatedthat 15%to30% 
of gallstone patients would be candidates for biliary lithotripsy2• 
The Kidney Stone Center of the Pacific initiated lithotripsy 
services for kidney stones in Hawaii in 1986 and is, therefore, the 
source of lithotripsy technological knowledge in the state. The 
KSCoP assumed the responsibility of assessing the status of the 
clinical efficacy of biliary lithotripsy and, if satisfied, planned to 
apply for a Certificate ofNeed (CON) to introduce biliary lithotripsy 
in Hawaii. A letter of intent was filed with the State Health 
Planning and Development Agency. 
Methods 
The KSCoP invited a group of physicians (gastroenterolo-
gists, general surgeons, radiologists, urologists), hospital admin-
istrators, technicians and consultants to organize themselves into 
a group to consult with the major vendors of biliary lithotripters 
and advise how to proceed with a CON application. The group met 
with 4 vendors during the period February to May 1990: Domier, 
Siemens, Technomed and Medstone. Both a sales representative 
and a physician currently using the respective machines were 
present at each vendor meeting. Presentations included informa-
tion pertaining to: Patient selection, procedure technique, tech-
nology used, localization method, results of clinical trials, com-
parison to other machines and acquisition and maintenance costs. 
All of the lithotripters reviewed were second-generation, 
dual-purpose (kidney and biliary) devices. Whereas first genera-
tion devices required the patient to be partially immersed in a large 
water bath under general anesthesia, second generation devices 
are "dry", and the patient can be under either general anesthesia or 
intravenous sedation, but conscious. The "dry" devices included 
a patient-positioning treatment table and some type of fluid-filled 
coupling system, such as a fluid-filled bellows or a mini-water 
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bath built into the treatment table, or a fluid-filled bag. 
The Siemens Lithostar Plus, Technomed Sonolith 3000 and 
Medstone STS are already FDA-approved for kidney lithotripsy. 
The Domier MPL 9000 does not yet have approval for kidney 
lithotripsy (no device has yet received FDA market approval for 
biliary lithotripsy). 
The KSCoP' s existing unit is a Domier HM3, a first genera-
tion device. The group conducting the analysis also considered 
whether a second generation device should be acquired to replace 
the HM3, or be used as a back-up for kidney lithotripsy until FDA 
approval is obtained for biliary lithotripsy. 
Subsequent to KSCoP' s meetings with the vendors, the FDA 
announced a revised protocol for a Phase II of clinical testing for 
biliary lithotripsy. Under Phase II, the clinical test results must be 
presented and compared between lithotripsy alone, lithotripsy 
together with bile acid therapy, and bile acid therapy alone. 
Results 
A summary of the distinguishing characteristics of each 
vendor's lithotripter follows. 
Dornier 
The Dornier Multipurpose Lithotripter (MPL) 9000 was 
operated at 10 clinical test sites for biliary lithotripsy under FDA 
Phase I protocol. Clinical data was presented to the FDA in 
October 1989 to seek pre-market approval. The FDA denied 
approval and requested follow-up of patients for 12 months. 
Dornier plans to continue clinical test trials under FDA Phase II 
protocol, but at a reduced number of test sites. 
The MPL 9000uses a spark-gap power source and ultrasound 
for localization and visualization. The purchase price is $1.35 
million. An x-ray attachment also is available for an additional 
$150,000 to $200,000. The annual maintenance fee is $105,000; 
the manufacturer recommends spark-plug replacement after each 
procedure. The cost per spark plug is $165; 2 are used per 
procedure. 
A trade-in credit is available for the HM3 (the unit currently 
in use at the Kidney Stone Center), ranging from $250,000 to 
$400,000 depending on the age of the equipment. 
The MPL 9000 does not yet have FDA approval for kidney 
lithotripsy, but the vendor is projecting market approval in 1991. 
The physician using the device reported that once the procedure 
has been mastered, average treatment time is approximately 30 
minutes for kidney stones and 90 minutes for gallstones. The 
shock wave treatment technique involves first fragmenting the 
stone, then pulverizing it. He performed the procedures without 
general anesthesia and reported there were no complications. No 
adjustments are necessary to switch from a kidney to a biliary 
procedure except that the anesthesia machine had to be moved 
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from one end of the table to the other. 
The MPL 9000 is a fixed device; a mobile model is not 
available. Anatomical positioning is done through the use of a 5-
axis table. The therapeutic C-arm can be positioned above or 
below the treatment table. The therapeutic unit consists of an 
impulse generator, an electrode, an ellipsoid and a water cushion 
connected to a closed system of circulating water. 
Siemens 
The Siemens Lithostar Plus is available in both fixed and 
mobile models. There are 10 fixed clinical test sites and one mobile 
clinical test site for biliary lithotripsy. The Lithostar Plus is already 
FDA approved for kidney lithotripsy. Siemens plans to continue 
conducting clinical test trials under FDA Phase II protocol. 
The Lithostar Plus uses an electromagnetic power source and 
has integrated ultrasound and x-ray localization. The electromag-
netic source produces lower energy shocks than spark -gap power 
sources and pulverizes rather than fragments the kidney stones. 
For use on gallstones, a biliary attachment shock head capable of 
doubling the energy is attached. The gallstone is cracked at a 
higher energy level, then the power is lowered to pulverize the 
stone. Acquisition price is $1.4 million for the fixed model and 
$1.8 million for the self-contained mobile ·model. The biliary 
attachment is an additional $300,000, annual maintenance fee is 
$96,000 for kidney, and an additional $24,000 for biliary. The 
shock heads are recommended to be replaced every 1 million 
shocks (approximately 200 procedures). Replacement cost is 
$7,400 for the shock head. A trade-in credit for the HM3 is 
available for $400,000. 
The Lithostar Plus is designed as a urologic work station. Its 
therapeutic unit is ceiling mounted to allow access from all sides 
of the treatment table. Standard urologic accessories can be 
mounted on the table. A radiographic bucky cassette is built into 
the table to permit x-rays for checking on stone fragmentation 
without moving the patient. The table is computer controlled on 3 
axes for positioning. The shock wave tube is water-filled and 
coupling bellows are placed against the patient's skin. 
Because of the lower energy used, the procedure is almost 
pain-free and the physician reported usually using no anesthesia 
and performing most procedures on an outpatient basis. The 
physician using the device noted that clinical tests in Europe were 
having better results than in the United States. The reason given 
was that the U.S. sites were not using the low energy technique 
properly; treatment time averaged about 1 hour per case. 
Biliary clinical test trials on 101 patients averaged 2.3 treat-
ments per patient to obtain fragments of less than 4 mm. More 
clinical test data is needed before the request for FDA biliary 
approval is filed. 
Technomed 
The Technomed Sonolith 3000 is available in fixed and trans/ 
mobile models. There were 9 fixed and 3 trans/mobile clinical test 
sites for FDA Phase I protocol for biliary lithotripsy. The Sonolith 
3000 is already FDA approved for kidney lithotripsy. Technomed 
plans to continue clinical test trials under FDA Phase II protocol; 
however, the number of sites has not yet been determined. 
The Sonolith 3000 uses a spark-gap power source with 
continuous-feed electrodes that may be used on 100 patients 
before replacement. Replacement is included in the annual main-
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tenance fee. Ultrasound is used for stone localization. Acquisition 
price is $1.09 million for the fixed and $1.235 million for the trans/ 
mobile plus an additional $70,000 for the transport van. Annual 
maintenance fee is $110,000 for the fixed and $130,000 for the 
trans/mobile. The maintenance fee is reduced by $20,000 if 
ultrasound is excluded from the Technomed maintenance and 
arranged for separately. Portable x-ray also is availablefor$50,000. 
The shock wave generator of the Sonolith 3000 is mounted at 
the base of the water basin/"minipool" coupling. The frame of the 
mobile sub-assembly supports the water basin. The water process-
ing system is contained within the treatment module. Method of 
anesthesia is by intravenous sedation of the conscious patient or 
none at all. 
Medstone 
The Medstone Shockwave Therapy System (STS) is avail-
able in fixed and mobile models. There were 10 fixed clinical test 
sites and 2 mobile clinical test sites for FDA Phase I protocol for 
biliary lithotripsy. The STS is already FDA approved for kidney 
lithotripsy. 
Medstone presented clinical data to the FDA in October 1989 
to seek pre-market approval for biliary lithotripsy. The FDA 
denied approval and requested longer and more consistent follow-
up on more patients. Medstone' s use of historical controls did not 
adequately clarify the device's efficacy for gallbladder applica-
tions. Stone-free rates at six months, one of the outcomes reported 
varied at different test sites from 0% at 3 sites to 66% at one site. 
Medstone has temporarily discontinued biliary test trials and as of 
December 1990 did not plan to pursue the FDA Phase II protocol 
testing. The device is still marketed, however, for kidney lithotripsy. 
The STS uses a spark-gap power source and integrated 
ultrasound and x-ray for localization and visualization. The acqui-
sition price is $1.375 million for either the fixed or mobile device. 
The trailer for the self-contained mobile unit costs an additional 
$300,000, the annual maintenance fee is $125,000 and the device 
uses one spark plug which is replaced after each procedure. The 
cost of a spark plug is $270. Medstone also has an alternative 
pricing structure which includes a sliding-scale, fee-for-service 
cost based on patient volumes ranging from $2,000 a patient to 
$750 a patient. There is no maintenance fee or spark-plug re-
placement cost on the fee-for-service pricing. 
The STS shock-wave generator is located beneath a custom-
ized x-ray treatment table. The shock -wave is focused by a curved 
reflector as it travels through water-based fluids contained in the 
reflector. A fluid-filled disposable bag couples the patient to the 
shock-wave generator and a computer assists in positioning the 
patient. The table is adjustable in 3 dimensions. The STS also can 
be used for general x-ray, ultrasound, and urological procedures. 
Lithotripsy procedures on the STS average 45 to 90 minutes in 
duration. 
Table 1 compares thekeyfeaturesofeachlithotripteranalyzed. 
Discussion 
The use of drugs and biologicals 
Although cholecystectomy today is considered the safest, 
most effective and most recommended treatment for gallstones, 
the pharmaceutical and biological approaches also are under 
study. Two types of dissolving agents being investigated with 
some success include: (a) Orally administered bile acid compound 
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HAWAII MEDICAL JouRNAL-VoL. 52, No. 3-MARCH 1993 
SECOND GENERATION LITHOTRIPTERS (Continued from page 68) 
(ursodeoxycholic acid). The medication is administered over a I-
to 2-year treatment period. A dissolving effect has been achieved 
only in stones composed mainly of cholesterol and no calcium 
salts, pigments or mucus. A research study reported a 10% 
recurrence rate within 1 year after discontinuation of bile acid 
medication3; (b) Catheter -administered cholesterol-solvent methyl 
tert -butyl ether (MTBE) dissolves the stones more rapidly than do 
bile acid compounds. MTBE dissolves cholesterol stones in an 
average of 12.5 hours; advanced equipment may reduce the time 
to less than 4 hours. The treatment must be administered carefully 
through a percutaneous catheter4. 
A new surgical option 
A new surgical procedure, laparoscopic cholecystectomy, 
has been introduced and now is being performed in Hawaii. The 
procedure involves the physician making only a few small (ap-
proximately half-inch) incisions in the patient's abdomen. An 
optical scope (laparoscope) is inserted through one incision into 
the abdominal cavity. The physician, viewing the operation on a 
video screen, removes the gallbladder through one of the small 
incisions. Electrocautery units and lasers are used to detach and 
remove the gallbladder. The advantages of the procedure include5·6: 
• Only 2 to 3 days recuperation, compared to 3 to 4 weeks for 
conventional cholecystectomy surgery. 
• Reduced hospital stay, thereby reducing costs to the patient. 
• Reduced scarring due to the small incision. 
• Greater comfort. 
Conclusions 
Following the analysis, the group reached the 
following conclusions: Lithotripter technology is still evolving; 
biliary applications of lithotripsy are still investigational; the 
clinical efficacy of biliary lithotripsy has yet to be proven; no 
vendor is likely to receive FDA approval to market biliary 
lithotripters in the United States much before 1993; only about 
15% to 30% of gallstone patients would be candidates for biliary 
lithotripsy due to its limited indication under the current FDA 
protocol for investigational use for stones of only a certain size, 
composition and location; and the advent of laparoscopic 
cholecystectomy presents a cost effective, lower morbidity, surgi-
cal option to traditional cholecystectomy surgery for patients 
suffering from gallbladder disease. 
Key Features For Lithotripter Comparison As Of December 1990 
FDA 
Phase II 
Acquisition Trade in Annual Locali- FDA ARRroval Biliary 
List Price Credit Maintenance Technology zation Kidney Biliary TestTrials 
Domier Fixed MPL 9000 $1.35 $250,QO- $105,000 Spark Gap Single Ultrasound No- No Yes 
million 400,00 Use Electrode X -ray Attach- Project 1991 
mentAvail 
($150,QOO-
200,000) 
Siemens Fixed $1.4million $400,000 Kidney- Electromagnetic UHrasound Yes No Yes 
Uthostar Plus +$300,000 $96,000+ &X-ray 
Biliary Attachment Biliary $24,000 Integrated 
Siemens Seff Contained $1.8million $400,000 Kidney- Electromagnetic UHrasound Yes No Yes 
Mobile Uthostar Plus +$300,000 $96,000+Biliary &X-ray 
Biliary Attachment $24,000 Integrated 
T echnomed Trans/ $1.235 million Willing to $130,000 Spark Gap UHrasound Yes No Yes 
Mobile Sonolith 3000 +Van Discuss (-$20,000 if Continuous Portable X-ray 
($70,000) unrasound excluded) Feed X-ray Avail 
(Includes replacement Electrode 
Electrodes if needed) 
T echnomed Fixed $1.09million Willing to $110,000 Spark Gap UHrasound Yes No Yes 
Sonolight 3000 Discuss (-$20,000if continuous 
unrascund excluded) feed electrode Portable X-ray 
(lndudes replacement avail ($50,000) 
electrodes if needed 
Medstone Fixed STS $1.375 million Yes- $125,000 Spark Gap- UHrasound Yes No TID*-
or Fee-for- Negotiate ($0on Fee- Single Use &X-ray 
Service Amount lor Service) Electrode Integrate 
($2,000 to $?50/patient) 
Medstone Seff $1.375 million Yes- $125,000 Spark Gap- UHrasound Yes No TID* 
Contained MobHe +Trailer Negotiate Single Use &X-ray 
STS ($3000,000) Amount Electrode lnteQrated 'Temporarily Discontinued 
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The overall conclusion of the analysis is that biliary lithotripsy 
should not be introduced in Hawaii until the clinical efficacy and 
cost benefit of the service can be demonstrated. 
The KSCoPwill continue to monitor the technologic progress 
of biliary lithotripsy and alternative treatments of gallstones. At 
such time that a responsible decision can be reached that Hawaii 
would benefit from the availability of biliary lithotripsy, the 
KSPoP will submit a CON application to establish the service in 
Hawaii. 
The group further concluded that a second generation device 
should not be acquired at this time as either a replacement for the 
current Dornier HM3 or as a back-up. Major reasons include: The 
cost of health care would be unnecessarily increased without any 
improvement in the quality of care; additional capacity is still 
available from the existing HM3; the State does not have a need 
for a second kidney lithotripter as yet; physicians using the 
existing HM3 are satisfied with its performance and the device has 
rarely needed down time due to mechnical problems; physicians 
in the group conducting the analysis preferred the use of general 
anesthesia because of the controlled respiration which reduces the 
time required to perform the procedure as well as the number of 
shock waves required; and physicians noted that re-treatrnent 
appeared to be necessary more often when the second generation 
devices were used (21%) 7, were used as compared with the current 
experience with the HM3 in Hawaii (9% )8. 
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